Accounting & Tax
Credit & Capital
Risk & Compliance
N.Y. State Regulator Fines PwC for Watering Down Report
The accounting firm's regulatory consulting unit agrees to settle accusations over a Bank of Tokyo-Mitsubishi report for $25 million.
Dollar General Outbids Rival for Family Dollar Stores
If Dollar General's offer is accepted, the combined company would have 20,000 stores, $28 billion in sales and a lot of leverage.
SEC to Clamp Down on Credit-Ratings Agencies
Credit-ratings agencies are bracing for new regulations that will tackle problems with the "issuer pays" model and a lack of disclosures to investors.
Alibaba Uncovers Questionable Accounting By Media Unit
As the Chinese Internet giant gears up for its IPO, managers of a new subsidiary discover accounting irregularities.
Chiquita Rebuffs Takeover Bid
Chiquita's rejection of the offer from Cutrale and Safra Group means that it will proceed with a deal that would move its tax domicile to Europe.
Accounting & Tax
New Highway Bill Offers Pension-Funding Relief
Companies may have to contribute less now, but that may be just 'kicking the can down the road.'
Eurozone Economy Flatlines in 2Q
As the region gets ready to feel the impact of sanctions on Russia, its two largest economies report dismal growth numbers.
Human Capital & Careers
Stress-Free Vacationing 101
Regardless of the position you hold in the corporate food chain, taking a vacation is necessary. So how do you prepare for one that's free of work worries?
No Heat in July Retail Sales Numbers
Limited wage growth, coupled with considerable pockets of unemployed workers, contributed to weak retail sales to start the third quarter.
Boston Fed President Urges Repo Market Reform
Though short-term borrowing peaked before the recession, some regulators feel the repo market is still especially vulnerable to financial stress.
A Carbon Tax Could Eliminate Tax Inversions
As tax inversion deals increase, two experts propose a quirky solution: use a carbon tax to fund an overhaul of the U.S. corporate tax code.
Jilted at the NASDAQ Altar
A key investor balks at buying IPO shares in Vascular Biogenics, voiding trading in the stock only six days after the biotech firm went public.
Get the latest news from the CFO
Updated daily and weekly